Any day now. Almost. That is, any day now, the creakingly slow mode of the FDA and what seems to be its increased willingness to delay approvals might get fixed, or be on its way to getting fixed. (BioWorld Financial Watch)
As accusations many of them contained in lawsuit papers filed by shareholders fly right and left in the ImClone Systems Inc. imbroglio related to Erbitux (cetuximab), bystanders are trying to sort out what happened. (BioWorld Financial Watch)
